Genentech has signed an exclusive worldwide license agreement with Chinese pharmaceutical firm Jemincare to allow the latter to develop and commercialize JMKX002992, an androgen receptor degrader being developed for prostate cancer.
Jemincare, a leading pharmaceutical company from China, announced today that it and its wholly owned subsidiary company, Shanghai Jemincare...
Finland's Orion Corporation has entered into an agreement with Chinese Jemincare, through which Orion will receive exclusive global development and commersialisation rights, excluding the Greater China area (mainland China, Hong Kong, Macau and Taiwan), for a potent and selective NaV 1.8 blocker for the treatment of acute and chronic pain. Orion will also receive ownership to certain key patent applications relating to the compound within its own territory.
SHANGHAI , Sept. 15, 2021 / PRNewswire / - Recently, the Jemincare Group said it has completed Phase I clinical testing of a new coronavirus-specific neutralizing antibody the group has developed (project code: JMB2002) .
SHANGHAI, Sept. 13, 2021 /PRNewswire/ -- Recently, Jemincare group has declared that it has completed phase I clinical trial of self-developed novel coronavirus specific neutralizing antibody (Project code: JMB2002).
Wockhardt Bio, a subsidiary of Wockhardt, a leader in the discovery of novel antibiotics and Jiangxi Jemincare Group Company, China, have partnered for Wockhardt’s novel patented antibiotic WCK 4873 in People’s Republic of China, Hong Kong, Macau and Taiwan for the treatment of community-acquired bacterial pneumonia and other respiratory tract infections.
SHANGHAI, April 2, 2021 /PRNewswire/ -- On March 31, 2021, Jemincare group announced that their anti-SARS-CoV-2 neutralizing antibody, JMB2002, independently developed by Jemincare Shanghai Research Center, was approved by FDA for clinical trial in the United States.
SHANGHAI, April 2, 2021 /PRNewswire/ -- On March 31, 2021, Jemincare group announced that their anti-SARS-CoV-2 neutralizing antibody, JMB2002, independently developed by Jemincare Shanghai Research Center, was approved by FDA for clinical trial in the United States.